{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:47:30Z","timestamp":1769730450584,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015138","name":"J. Willard and Alice S. Marriott Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008102","name":"University of Cincinnati","doi-asserted-by":"publisher","award":["K23MH120503"],"award-info":[{"award-number":["K23MH120503"]}],"id":[{"id":"10.13039\/100008102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016939","name":"Myriad Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.cct.2021.106587","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T08:55:07Z","timestamp":1633337707000},"page":"106587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder"],"prefix":"10.1016","volume":"110","author":[{"given":"Anna I.","family":"Guerdjikova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Romo-Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2021.106587_bb0005","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.biopsych.2012.11.020","article-title":"The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys","volume":"73","author":"Kessler","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cct.2021.106587_bb0010","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/eat.22427","article-title":"Healthcare costs and resource utilization of patients with binge-eating disorder and eating disorder not otherwise specified in the Department of Veterans Affairs","volume":"48","author":"Bellows","year":"2015","journal-title":"Int. J. Eat Disord."},{"key":"10.1016\/j.cct.2021.106587_bb0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1017\/S1092852915000759","article-title":"Overview of the treatment of binge eating disorder","volume":"20","author":"McElroy","year":"2015","journal-title":"CNS Spectr."},{"key":"10.1016\/j.cct.2021.106587_bb0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cct.2021.106587_bb0025","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/npp.2015.275","article-title":"Lisdexamfetamine dimesylate for adults with moderate to severe binge eating disorder: results of two pivotal phase 3 randomized controlled trials","volume":"41","author":"McElroy","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.cct.2021.106587_bb0030","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamapsychiatry.2017.1889","article-title":"Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized controlled clinical trial","volume":"74","author":"Hudson","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cct.2021.106587_bb0035","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13068","article-title":"Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, flexible-dose clinical trial","volume":"81","author":"McElroy","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2021.106587_bb0040","first-page":"1","article-title":"Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial","author":"Grilo","year":"2020","journal-title":"CNS Spectr."},{"key":"10.1016\/j.cct.2021.106587_bb0045","unstructured":"https:\/\/news.sunovion.com\/PRESS-RELEASES\/PRESS-RELEASES-DETAILS\/2020\/SUNOVION-DISCONTINUES-DASOTRALINE-PROGRAM\/DEFAULT.ASPX. Sunovion Discontinues Dasotraline Program 2013."},{"key":"10.1016\/j.cct.2021.106587_bb0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/jpet.118.248120","article-title":"Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor","volume":"366","author":"Baladi","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.cct.2021.106587_bb0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ana.25423","article-title":"A randomized study of solriamfetol for excessive sleepiness in narcolepsy","volume":"85","author":"Thorpy","year":"2019","journal-title":"Ann. Neurol."},{"issue":"11","key":"10.1016\/j.cct.2021.106587_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1164\/rccm.201806-1100OC","article-title":"Solriamfetol for excessive sleepiness in obstructive sleep apnea (TONES 3): a randomized controlled trial","volume":"199","author":"Schweitzer","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cct.2021.106587_bb0065","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.chest.2018.11.005","article-title":"Solriamfetol for the treatment of excessive sleepiness in OSA: a placebo-controlled randomized withdrawal study","volume":"155","author":"Strollo","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.cct.2021.106587_bb0070","unstructured":"https:\/\/pp.jazzpharma.com\/pi\/sunosi.en.USPI.pdf . Solfiramfetol Prescribing Information; 2019."},{"key":"10.1016\/j.cct.2021.106587_bb0075","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/0269881118796814","article-title":"A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor","volume":"32","author":"Carter","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.cct.2021.106587_bb0080","series-title":"Weight Change Associated With Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants With Narcoplesy or Obstructive Sleep Apnea SLEEP","volume":"Volume 42","author":"Malhotra","year":"2019"},{"key":"10.1016\/j.cct.2021.106587_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/eat.20798","article-title":"Sodium oxybate in the treatment of binge eating disorder: an open-label, prospective study","volume":"44","author":"McElroy","year":"2011","journal-title":"Int. J. Eat Disord."},{"key":"10.1016\/j.cct.2021.106587_bb0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/YIC.0000000000000079","article-title":"Armodafinil in binge eating disorder: a randomized, placebo-controlled trial","volume":"30","author":"McElroy","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2021.106587_bb0095","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.cct.2021.106587_bb0100","series-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P)","author":"First","year":"2002"},{"key":"10.1016\/j.cct.2021.106587_bb0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/1098-108X(199412)16:4<363::AID-EAT2260160405>3.0.CO;2-#","article-title":"Assessment of eating disorders: interview or self-report questionnaire?","volume":"16","author":"Fairburn","year":"1994","journal-title":"Int. J. Eat Disord."},{"key":"10.1016\/j.cct.2021.106587_bb0110","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","article-title":"Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants","volume":"164","author":"Posner","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2021.106587_bb0115","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/eat.22407","article-title":"Validation of the Yale-brown obsessive compulsive scale modified for binge eating","volume":"48","author":"Deal","year":"2015","journal-title":"Int. J. Eat Disord."},{"key":"10.1016\/j.cct.2021.106587_bb0120","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.cct.2021.106587_bb0125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.biopsych.2006.08.008","article-title":"Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study","volume":"61","author":"McElroy","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cct.2021.106587_bb0130","series-title":"Applied Longitudinal Analysis Hoboken","author":"Fitzmaurice","year":"2004"},{"key":"10.1016\/j.cct.2021.106587_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421003232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421003232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:54:47Z","timestamp":1761555287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421003232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":27,"alternative-id":["S1551714421003232"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106587","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106587","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106587"}}